AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Real needles
Number of subjects: 40
Study 31877377 — intervention group
Group type: COMPARATOR
Intervention: Sham needles
Number of subjects: 40
Study 31877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded condition
Number of subjects: 40
Study 31877377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sighted condition
Number of subjects: 40
Study 29283682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy plus long-term oxygen therapy
Number of subjects: 32
Study 29283682 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy only
Number of subjects: 32
Study 27422271 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 124
Study 27422271 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 124
Study 24969592 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal F, a light-cured resin-based sealant
Number of subjects: 419
Study 24969592 — intervention group
Group type: EXPERIMENTAL
Intervention: FUJI VII, a light-cured glass ionomer sealant
Number of subjects: 419
Study 24969592 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 419
Study 23412098 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + 400 mg upamostat (arm C)
Number of subjects: 95
Study 23412098 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + 200 mg upamostat (arm B)
Number of subjects: 95
Study 23412098 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (arm A)
Number of subjects: 95
Study 20456590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and lifestyle interventions
Number of subjects: 0
Study 18565142 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSymbioflor (an autolysate of cells and cell fragments of Enterococcus faecalis and Escherichia coli)
Number of subjects: 297
Study 18565142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 16641530 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural continuous infusion without an initial dose (continuous group)
Number of subjects: 61
Study 16641530 — intervention group
Group type: COMPARATOR
Intervention: Epidural continuous infusion with an initial dose (initial dose group)
Number of subjects: 61
Study 16641530 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (spinal group)
Number of subjects: 61
Study 12731612 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 45
Study 12731612 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling
Number of subjects: 45
Study 11050836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg t.i.d, i.v.
Number of subjects: 101
Study 11050836 — intervention group
Group type: COMPARATOR
Intervention: Cephradine 1 g q.i.d., i.v.
Number of subjects: 101
Study 8617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 60 minutes twice a week for 6 months
Number of subjects: 42
Study 8617907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific exercise regimen)
Number of subjects: 42
Study 1320536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% delta‐9‐tetrahydrocannabinol
Number of subjects: 6
Study 1320536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.55% delta‐9‐tetrahydrocannabinol
Number of subjects: 6
Study 1320536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% and 3.55% delta‐9‐tetrahydrocannabinol
Number of subjects: 6
Study 3776752 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical intervention (study group)
Number of subjects: 174
Study 3776752 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 30301475 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSuture Trainer Box Simulator (ESTBS)
Number of subjects: 37
Study 30301475 — intervention group
Group type: COMPARATOR
Intervention: Standard Laparoscopic Trainer (SLT)
Number of subjects: 37
Study 28033399 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth physiotherapeutic scoliosis-specific exercises (PSSE)
Number of subjects: 50
Study 28033399 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 50
Study 24702987 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 73
Study 24702987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 73
Study 24702987 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 73
Study 24702987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22143257 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily educational text messages for 180 days
Number of subjects: 962
Study 21695161 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 856
Study 21695161 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg/kg
Number of subjects: 856
Study 19855259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound (HRUS)
Number of subjects: 144
Study 19855259 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 144
Study 19855259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector computed tomography (CT)
Number of subjects: 144
Study 16965492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Number of subjects: 17
Study 14993078 — intervention group
Group type: EXPERIMENTAL
Intervention: Chizukit (herbal preparation containing 50 mg/mL of echinacea, 50 mg/mL of propolis, and 10 mg/mL of vitamin C)
Number of subjects: 430
Study 14993078 — intervention group
Group type: COMPARATOR
Intervention: Placebo elixir
Number of subjects: 430
Study 11469296 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated instrumentation using KaVo‐Endo Flash device with K‐Flexofiles
Number of subjects: 120
Study 11469296 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation using K‐Flexofiles and Hedstrom files
Number of subjects: 120
Study 11469296 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated instrumentation using ProFile system with rotary nickel‐titanium instruments
Number of subjects: 120
Study 9088587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg day‐1 for 14 days)
Number of subjects: 12
Study 9088587 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (100 mg)
Number of subjects: 12
Study 8259749 — intervention group
Group type: EXPERIMENTAL
Intervention: Early induction with oxytocin (6 hours after PROM)
Number of subjects: 362
Study 8259749 — intervention group
Group type: COMPARATOR
Intervention: Late induction with oxytocin (24 hours after PROM)
Number of subjects: 362
Study 8259749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late induction groups
Number of subjects: 362
Study 3883843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40
Study 3883843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 40
Study 30234415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovinol (250 mg per day)
Number of subjects: 16
Study 30234415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27396951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 473
Study 27396951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (alone or in combination with CCNU)
Number of subjects: 473
Study 25072529 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive radio-frequency diathermy (CRFD) local application (30 min)
Number of subjects: 27
Study 25072529 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive radio-frequency diathermy (CRFD) local application followed by whole-segment application (20 min)
Number of subjects: 27
Study 25072529 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRFD treatment followed by supplementary application)
Number of subjects: 27
Study 22772854 — intervention group
Group type: EXPERIMENTAL
Intervention: Borghi's approach (soft tissue depression)
Number of subjects: 54
Study 22772854 — intervention group
Group type: COMPARATOR
Intervention: Chayen's approach (iliac crest)
Number of subjects: 54
Study 22772854 — intervention group
Group type: EXPERIMENTAL
Intervention: Borghi's approach (soft tissue depression) in obese patients (BMI ≥30 kg/m(2))
Number of subjects: 54
Study 22772854 — intervention group
Group type: COMPARATOR
Intervention: Chayen's approach (iliac crest) in obese patients (BMI ≥30 kg/m(2))
Number of subjects: 54
Study 20192552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone-Square Pairings
Number of subjects: 0
Study 20192552 — intervention group
Group type: COMPARATOR
Intervention: Tone-Alone Presentations
Number of subjects: 0
Study 20192552 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of the Square
Number of subjects: 0
Study 20192552 — intervention group
Group type: EXPERIMENTAL
Intervention: RT Performance
Number of subjects: 0
Study 20192552 — intervention group
Group type: EXPERIMENTAL
Intervention: RT Perruchet Effect
Number of subjects: 0
Study 18983246 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 387
Study 18983246 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during pregnancy
Number of subjects: 387
Study 16028788 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (hearing aid fitting + home education program)
Number of subjects: 94
Study 16028788 — intervention group
Group type: COMPARATOR
Intervention: Control group (hearing aid fitting)
Number of subjects: 94
Study 16028788 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 94
Study 16028788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 12492183 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat intervention (TTI)
Number of subjects: 93
Study 12492183 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (UCC)
Number of subjects: 93
Study 10029033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for ICP management
Number of subjects: 24
Study 7496683 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiration group
Number of subjects: 100
Study 7496683 — intervention group
Group type: COMPARATOR
Intervention: Inspiration group
Number of subjects: 100
Study 2036812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 90
Study 2036812 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 90
Study 2036812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7144047 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (41 children) with frequent ambulatory checkups (22 times)
Number of subjects: 61
Study 7144047 — intervention group
Group type: COMPARATOR
Intervention: Nonactive group (20 children) with infrequent ambulatory checkups (8 times)
Number of subjects: 61
Study 7144047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent treatment based on diet and increased physical exercise for two years
Number of subjects: 61
Study 30690551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours of darkness (4D)
Number of subjects: 4000
Study 30690551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours of darkness (10D)
Number of subjects: 4000
Study 30690551 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing darkness (1D, 4D, 7D, 10D)
Number of subjects: 4000
Study 30690551 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender factors
Number of subjects: 4000
Study 28074446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg at Week 12, followed by Q4W for Weeks 16-60)
Number of subjects: 0
Study 28074446 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly for the first 12 weeks, followed by placebo at Week 12)
Number of subjects: 0
Study 26057484 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen/thrombin/autologous platelet haemostatic agent
Number of subjects: 109
Study 26057484 — intervention group
Group type: COMPARATOR
Intervention: Standard haemostatic methods only (Control)
Number of subjects: 109
Study 23592676 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (HP)
Number of subjects: 43
Study 23592676 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NP)
Number of subjects: 43
Study 23592676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (NP and HP)
Number of subjects: 43
Study 21469388 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatin sponge patch bonded repair group
Number of subjects: 112
Study 21469388 — intervention group
Group type: COMPARATOR
Intervention: natural repair group
Number of subjects: 112
Study 19460684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dornase alfa administered 30 minutes before airway clearance therapy (ACT)
Number of subjects: 0
Study 19460684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dornase alfa administered before bedtime or upon awakening
Number of subjects: 0
Study 19460684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dornase alfa
Number of subjects: 0
Study 17011315 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (0.5 mg/kg)
Number of subjects: 30
Study 15279069 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg, po)
Number of subjects: 10
Study 15279069 — intervention group
Group type: COMPARATOR
Intervention: CRH (1 microg/kg iv) given alone or after rosiglitazone
Number of subjects: 10
Study 10682964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% twice daily
Number of subjects: 378
Study 10682964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% three times daily
Number of subjects: 378
Study 10682964 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 378
Study 9340014 — intervention group
Group type: EXPERIMENTAL
Intervention: lomeprol
Number of subjects: 1200
Study 9340014 — intervention group
Group type: COMPARATOR
Intervention: iopromide
Number of subjects: 1200
Study 8497972 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous drain-blood transfusion
Number of subjects: 56
Study 8497972 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 56
Study 3113975 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg orally at bedtime)
Number of subjects: 20
Study 3113975 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (10 mg at bedtime)
Number of subjects: 20
Study 3113975 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg) and gonadotropin releasing hormone (100 micrograms)
Number of subjects: 20
Study 29273115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges (1:1 match savings)
Number of subjects: 48
Study 29273115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges PLUS (1:2 match savings)
Number of subjects: 48
Study 29273115 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 48
Study 27475887 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in hazardous drinking
Number of subjects: 307
Study 27475887 — intervention group
Group type: COMPARATOR
Intervention: Continued hazardous drinking
Number of subjects: 307
Study 27475887 — intervention group
Group type: COMPARATOR
Intervention: Anxiety and depressive symptoms
Number of subjects: 307
Study 25688038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 0
Study 25688038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23015608 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal alcohol screening and brief intervention (SBI) delivered by a practice nurse
Number of subjects: 1000000
Study 23015608 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal alcohol screening and brief intervention (SBI) delivered by a doctor
Number of subjects: 1000000
Study 23015608 — intervention group
Group type: COMPARATOR
Intervention: No programme
Number of subjects: 1000000
Study 20875112 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-centred diabetes information resources (diabetes diaries, carbohydrate recording sheets, information packs)
Number of subjects: 0
Study 20875112 — intervention group
Group type: COMPARATOR
Intervention: Currently available standard practice
Number of subjects: 0
Study 18231884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 128
Study 18231884 — intervention group
Group type: COMPARATOR
Intervention: Sterile water injections
Number of subjects: 128
Study 15193897 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Directions‐Health Centers intervention
Number of subjects: 1088
Study 11446242 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard symptom checklist
Number of subjects: 0
Study 11446242 — intervention group
Group type: COMPARATOR
Intervention: Modified checklist with bogus items
Number of subjects: 0
Study 11446242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both checklists
Number of subjects: 0
Study 9609509 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling and leadership training program (8 weeks + 8 weeks reinforcement)
Number of subjects: 204
Study 7509570 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estradiol transdermal system [Estraderm TTS] plus chlormadinone)
Number of subjects: 499
Study 7509570 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (verapipride)
Number of subjects: 499
Study 3281619 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 626
Study 3281619 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 626
Study 3281619 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus a diuretic
Number of subjects: 626
Study 3281619 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (unspecified)
Number of subjects: 626
Study 31627278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 68
Study 31627278 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 68
Study 28358253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.4 J/cm2 UV-A radiance (Group 1)
Number of subjects: 82
Study 28358253 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 J/cm2 UV-A radiance (Group 2)
Number of subjects: 82
Study 25463008 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fidelity simulation (3 sessions of 2 hours each)
Number of subjects: 35
Study 25463008 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face lectures (3 lectures covering forensic science topics)
Number of subjects: 35
Study 22986578 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 2595
Study 22986578 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 2595
Study 22986578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2595
Study 21598412 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure with Japanese Magnetic Pearl
Number of subjects: 55
Study 21598412 — intervention group
Group type: COMPARATOR
Intervention: Auricular acupressure only (Control)
Number of subjects: 55
Study 19910194 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery plus radiotherapy (RT)
Number of subjects: 749
Study 19910194 — intervention group
Group type: COMPARATOR
Intervention: Breast conserving surgery only
Number of subjects: 749
Study 19910194 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery with or without RT
Number of subjects: 749
Study 17130203 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 12
Study 17130203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12838696 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserving external jugular vein and cervical plexus
Number of subjects: 20
Study 12838696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preservation of external jugular vein and cervical plexus)
Number of subjects: 20
Study 10674115 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalable heroin (combined with oral methadone), administered seven days per week, three times per day for a period of six to twelve months.
Number of subjects: 625
Study 10674115 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable heroin (combined with oral methadone), administered seven days per week, three times per day for a period of six to twelve months.
Number of subjects: 625
Study 9341603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg/d
Number of subjects: 65
Study 9341603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 500 mg/d
Number of subjects: 65
Study 8408684 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition One (happy events)
Number of subjects: 90
Study 8408684 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition Two (sad events)
Number of subjects: 90
Study 8408684 — intervention group
Group type: COMPARATOR
Intervention: Condition Three (control - geography article)
Number of subjects: 90
Study 3317340 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg/day)
Number of subjects: 8
Study 3317340 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (160-240 mg/day)
Number of subjects: 8
Study 3317340 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg/day) and Verapamil (160-240 mg/day)
Number of subjects: 8
Study 30661686 — intervention group
Group type: EXPERIMENTAL
Intervention: FAVVA index
Number of subjects: 99
Study 29906015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-teledermatology
Number of subjects: 0
Study 26740194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 g plus nasal irrigation
Number of subjects: 0
Study 26740194 — intervention group
Group type: COMPARATOR
Intervention: Single nasal irrigation
Number of subjects: 0
Study 24919388 — intervention group
Group type: EXPERIMENTAL
Intervention: Yawning in motion condition
Number of subjects: 39
Study 24919388 — intervention group
Group type: COMPARATOR
Intervention: Non-yawning in motion condition
Number of subjects: 39